中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

Expanded Access Policy

Simcere pharma is a pharmaceutical company driven by innovative R&D, its mission is Providing Today’s Patients with Medicines of the Future across...

2024-04-19
SIM0500, Simcere Zaiming’s Tri-specific Antibody Candidate for Multiple Myeloma Received FDA Fast Track Designation

April 10, 2024. Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group Ltd., announced that the US Food and ...

2024-04-11
Simcere Zaiming will present six innovative researches at the 2024 AACR

March 25 2024. Simcere Zaiming, the oncology subsidiary of Simcere Pharmaceutical Group Ltd, will present its innovative research at the 2024 American...

2024-03-26
Simcere Zaiming announces global FIH dosing of USP1 inhibitor in clinical trial

On March 19, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group Ltd., announced that a Phase 1 cli...

2024-03-22
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666 Fax：025-85262330

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.